Medicine

Large Risk Reduction For Rivaroxaban In Blood Clot Prevention

December 9, 2007
Bengt Eriksson
Bengt Eriksson

REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.

Download this interview

Similar Interviews

  • Diabetic Patients: Some Benefits from Fibrates

    • Anthony Keech Among nearly 10 000 patients with maturity onset diabetes the use of fenofibrate to lower cholesterol produced a 24

  • Telomere Length Predicts Coronary Heart Disease Risk and Statin Response

    • NILESH SAMANI, Glenfield Hospital, Leicester REFERENCE: Lancet 2007; 369:107 A new genetic test could help predict which individuals will develop coronary heart

  • Eight Blood Pressure Genes Bring Promise For Drug Design

    • [caption id="attachment_844" align="alignnone" width="120" caption="Mark Caulfield"][/caption]Eight human genes have been recognised as modulating blood pressure by a team from London,

    1. I am a medicine student in Turkey and I am hoping to have my specialty in Orthotics. I am really glad to listen such a nice podcast about current progresses in the field, I hope I can make similar research in the field as well.

      Posted by Mert | May 12, 2008, 9:53 pm

    Post a comment